0.03
-0.0133(-32.05%)
Currency In USD
Address
400 Crossing Boulevard
Bridgewater, NJ 08807
United States of America
Phone
908 809 1300
Website
Sector
Healthcare
Industry
Biotechnology
Employees
125
First IPO Date
October 19, 2018
| Name | Title | Pay | Year Born |
| Mr. Brian A. Markison | Chairman, President, Chief Executive Officer & Principal Financial Officer | 525,000 | 1959 |
| Mr. James D. Schaub | Executive Vice President & Chief Operating Officer | 367,200 | 1982 |
| Mr. Christopher A. Klein | General Counsel & Secretary | 367,200 | 1965 |
| Mr. Michael J. DePetris | Principal Accounting Officer | 0 | 1977 |
| Mr. Jarret Miller | Executive Vice President of Human Resources | 0 | N/A |
| Dr. Tina Marie deVries Ph.D. | Executive Vice President of R&D | 0 | 1961 |
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.